Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous adipose derived mesenchymal stem cells · 1 trial · 2 indications
Target limb vascularization would be quantified by a dedicated software, MetaMorph® v.6.3, by using Angiogenesis Tube Formation application module. Neovasculogenesis would be the difference between vascularization at baseline and 6 months follow-up.
| Arm | Type | Description |
|---|---|---|
| Mesenchymal stem cells 0,5 million * weight (kg) | ACTIVE_COMPARATOR | Group of low dose of Mesenchymal stem cells. |
| Mesenchymal stem cells 1 million * weight (kg) | ACTIVE_COMPARATOR | Group of mid dose of mesenchymal stem cells |
| Controlled group | NO_INTERVENTION | Controlled group with no intervention |
| Name | Type | Description |
|---|---|---|
| Autologous adipose derived mesenchymal stem cells | DRUG | Intra-arterial administration through a selective cannulation of target common femoral artery |
Inclusion Criteria: * Diabetes, type 1 or 2 * Critical Limb Ischemia (Rutherford Becker Class II,III or IV)of at least one limb. * No options for target limb revascularization. Exclusion Criteria: * Cancer antecedent in the last two years * Current limb infection or limb gangrene
Autologous adipose derived mesenchymal stem cells is an investigational cell therapy being studied for Critical Limb Ischemia (CLI), a severe form of peripheral artery disease. It is being developed by Design Therapeutics, Inc. (NASDAQ: DSGN) and is currently in Phase 1 clinical development.
Autologous adipose derived mesenchymal stem cells is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker DSGN. The therapy is in Phase 1 clinical development for the treatment of Critical Limb Ischemia (CLI).
Autologous adipose derived mesenchymal stem cells is in Phase 1 clinical development. It is an investigational therapy for Critical Limb Ischemia (CLI) and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
Autologous adipose derived mesenchymal stem cells has one completed Phase 1 trial, NCT01257776, titled 'Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients.' The study enrolled 33 participants in Spain and included patients with Critical Limb Ischemia and diabetes.
Yes, Autologous adipose derived mesenchymal stem cells refers to the same investigational therapy as human adipose derived mesenchymal stem cells. The completed clinical trial NCT01257776 uses the latter name in its title, while the drug asset is formally listed as Autologous adipose derived mesenchymal stem cells.